Yumiko Ishizuka 研究室

AI 要約（直近 5 年の研究成果）

※ AI（Claude）が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。

研究成果（29 件）

• [2026] Revisiting nuclear grade as a high-risk marker for predicting upgrade in ductal carcinoma in situ
  DOI: https://doi.org/10.1016/j.humpath.2026.106172
• [2026] Clinical Outcomes and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A Real-World Data Analysis
  DOI: https://doi.org/10.14740/wjon2713
• [2025] Evaluating the quality of Japanese YouTube videos on breast cancer treatment using PRHISM: comparison by source credibility
  DOI: https://doi.org/10.1007/s12282-025-01796-2
• [2025] Breast tumors with intermediate ER expression differ biologically from ER-low tumors and exhibit a more favorable prognosis
  DOI: https://doi.org/10.1007/s12282-025-01745-z
• [2025] Assessing the Reliability and Validity of Principles for Health-Related Information on Social Media (PRHISM) for Evaluating Breast Cancer Treatment Videos on YouTube: Instrument Validation Study
  DOI: https://doi.org/10.2196/66416
• [2025] A Case of Breast Cancer with Cystic Axillary Lymph Node Metastasis
  DOI: https://doi.org/10.70352/scrj.cr.25-0163
• [2024] Clinicopathological characteristics of Japanese patients with breast cancer and <scp><i>MET</i></scp> exon 14 skipping alterations
  DOI: https://doi.org/10.1111/his.15382
• [2024] Characterization of breast cancer tumors in older patients who show de novo resistance to endocrine therapy
  DOI: https://doi.org/10.1038/s41598-024-83895-2
• [2024] Attempt to Substitute the Oncotype DX Breast Recurrence Score® Test by Histopathological Factors and MUC1 Protein Expression
  DOI: https://doi.org/10.21873/cdp.10349
• [2024] Absolute lymphocyte count as a biomarker for best supportive care transition in metastatic breast cancer
  DOI: https://doi.org/10.1136/spcare-2024-004989

科研費（0 件）

まだデータがありません（KAKEN 取り込み後に表示）。

所属学会・役職（0 件）

まだデータがありません（学会データ連携後に表示）。